Quince Therapeutics (QNCX) to Release Quarterly Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect Quince Therapeutics to post earnings of ($0.24) per share for the quarter.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The business had revenue of $0.17 million for the quarter. On average, analysts expect Quince Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quince Therapeutics Stock Down 1.0 %

Shares of NASDAQ:QNCX opened at $1.02 on Friday. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The firm’s 50-day simple moving average is $1.21 and its 200-day simple moving average is $1.52. The company has a market cap of $45.01 million, a price-to-earnings ratio of -0.82 and a beta of 0.83.

Analyst Ratings Changes

QNCX has been the topic of a number of analyst reports. D. Boral Capital dropped their target price on Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, March 25th. Oppenheimer started coverage on Quince Therapeutics in a research note on Monday, March 24th. They issued an “outperform” rating and a $10.00 price target on the stock. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Quince Therapeutics presently has a consensus rating of “Buy” and an average price target of $8.00.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.